Condition: Amyotrophic Lateral Sclerosis (ALS) · Sponsor: Novabio Therapeutics
An open, multi- center phase Ⅰ clinical study evaluating the safety and efficacy of autologous human polyclonal regulatory T cell injection (NP001 cell injection) in patients with Neurodegenerative diseases (ALS).
This description comes directly from the study's public registry record.
Mingqi Lu, MD., PhD · 609-716-7786; +86 15800843507 · lumingqi@novabiotx.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06671236